



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

May 31, 2017

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Acquisition of Brand "Neksium" from AstraZeneca AB, Sweden ("AstraZeneca")**

**Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

This is to inform you that the Company has entered into an Acquisition Agreement with AstraZeneca AB, Sweden ("AstraZeneca"), pursuant to which the brand "Neksium" is being acquired by the Company in India for a consideration of Rs. 75 Crores, subject to completion of necessary conditions precedent.

Neksium (*esomeprazole*) complements the Company's existing product portfolio in the gastrointestinal (GI) therapeutic area.

We request you to kindly take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

Prajeet Nair

Company Secretary

CIN: L24231MH1950PLC008311

✉ [contactus.india@pfizer.com](mailto:contactus.india@pfizer.com)

🌐 [www.pfizerindia.com](http://www.pfizerindia.com)